Healthcare / Medical DevicesShenzhen
$11.51
-0.19 (-1.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $7.9M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
N/A
•EV/EBITDA
122.7x
↑ROE
-1.4%
↓Gross Margin
48.0%
↓Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.1%
FCF CAGR
—
FCF margin
-5.8%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $468.0M · net income $-24.4M · FCF $-27.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $468.0M | $468.0M | $479.8M | $746.9M | $712.1M |
| Net Income | $-24.4M | $-24.4M | $-77.9M | $165.8M | $196.2M |
| EBITDA | $38.1M | $38.1M | $-10.6M | $258.8M | $259.1M |
| EPS | -0.06 | -0.06 | -0.19 | 0.40 | 0.48 |
| Gross Margin | 48.0% | 48.0% | 49.3% | 57.6% | 47.5% |
| Operating Margin | -3.0% | -3.0% | 0.2% | 24.2% | 17.2% |
| Net Margin | -5.2% | -5.2% | -16.2% | 22.2% | 27.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.42 | 0.51 | 0.82 |
| Current Ratio | 7.80 | 7.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.2M | $-27.2M | $7.9M | $150.3M | $22.2M |
| Returns | |||||
| ROE | -1.4% | -1.4% | -4.2% | 8.1% | 10.2% |
| Valuation | |||||
| P/E | — | — | — | 50.08 | 63.21 |
| EV/EBITDA | 122.67 | 122.67 | — | 34.31 | 48.58 |
| P/B | 2.70 | 2.70 | 3.24 | 4.06 | 6.43 |
| Growth & Yield | |||||
| Revenue Growth | -2.5% | -2.5% | -35.8% | 4.9% | — |
| EPS Growth | 68.4% | 68.4% | -147.5% | -16.7% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.19 → -0.06
Residual
-19.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.